Novel and highly recurrent chromosomal alterations in Sézary syndrome.

This study was designed to identify highly recurrent genetic alterations typical of Sézary syndrome (Sz), an aggressive cutaneous T-cell lymphoma/leukemia, possibly revealing pathogenetic mechanisms and novel therapeutic targets. High-resolution array-based comparative genomic hybridization was done on malignant T cells from 20 patients. Expression levels of selected biologically relevant genes residing within loci with frequent copy number alteration were measured using quantitative PCR. Combined binary ratio labeling-fluorescence in situ hybridization karyotyping was done on malignant cells from five patients. Minimal common regions with copy number alteration occurring in at least 35% of patients harbored 15 bona fide oncogenes and 3 tumor suppressor genes. Based on the function of the identified oncogenes and tumor suppressor genes, at least three molecular mechanisms are relevant in the pathogenesis of Sz. First, gain of cMYC and loss of cMYC antagonists (MXI1 and MNT) were observed in 75% and 40% to 55% of patients, respectively, which were frequently associated with deregulated gene expression. The presence of cMYC/MAX protein heterodimers in Sézary cells was confirmed using a proximity ligation assay. Second, a region containing TP53 and genome maintenance genes (RPA1/HIC1) was lost in the majority of patients. Third, the interleukin 2 (IL-2) pathway was affected by gain of STAT3/STAT5 and IL-2 (receptor) genes in 75% and 30%, respectively, and loss of TCF8 and DUSP5 in at least 45% of patients. In sum, the Sz genome is characterized by gross chromosomal instability with highly recurrent gains and losses. Prominent among deregulated genes are those encoding cMYC, cMYC-regulating proteins, mediators of MYC-induced apoptosis, and IL-2 signaling pathway components.

[1]  E. Jordanova,et al.  Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Willemze,et al.  Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sézary Syndrome Identified by Gene Expression Analysis , 2004, Cancer Research.

[3]  H. Tanke,et al.  Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma. , 2007, Cancer genetics and cytogenetics.

[4]  R. Clark,et al.  Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. , 2006, Blood.

[5]  Eric B Haura,et al.  Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer , 2005, Nature Clinical Practice Oncology.

[6]  H. Tanke,et al.  Insights from genomic microarrays into structural chromosome rearrangements , 2005, American journal of medical genetics. Part A.

[7]  L. Morsberger,et al.  Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: Search for recurrent chromosome abnormalities , 2006, Genes, chromosomes & cancer.

[8]  S. Whittaker,et al.  Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. , 2003, Blood.

[9]  G. Evan,et al.  Myc-Is this the oncogene from Hell? , 2002, Cancer cell.

[10]  C. Geisler,et al.  Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells , 2001, Leukemia.

[11]  J. Aster,et al.  c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. , 2006, Genes & development.

[12]  P. Bouillet,et al.  Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Baylin,et al.  p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3 , 1995, Nature Genetics.

[14]  I. D'Agnano,et al.  Oligopeptides impairing the Myc‐Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity , 2007, Journal of cellular physiology.

[15]  P. Nowell,et al.  Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Carolina Wählby,et al.  In Situ Detection of Phosphorylated Platelet-derived Growth Factor Receptor β Using a Generalized Proximity Ligation Method* , 2007, Molecular & Cellular Proteomics.

[17]  E. Sausville,et al.  Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary syndrome. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Whittaker,et al.  Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome. , 2003, Cancer research.

[19]  P. Krammer,et al.  CD95's deadly mission in the immune system , 2000, Nature.

[20]  J. Cleveland,et al.  Mnt Loss Triggers Myc Transcription Targets, Proliferation, Apoptosis, and Transformation , 2004, Molecular and Cellular Biology.

[21]  S. Whittaker,et al.  Molecular cytogenetic characterization of Sézary syndrome , 2003, Genes, chromosomes & cancer.

[22]  Rob Leurs,et al.  CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. , 2003, Blood.

[23]  A. Puisieux,et al.  A twist for survival and cancer progression , 2005, British Journal of Cancer.

[24]  R. Dummer,et al.  Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells. , 2001, The Journal of investigative dermatology.

[25]  C. Zahnow,et al.  Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. , 2004, Cancer cell.

[26]  N. Neamati,et al.  Small molecule inhibitors of Stat3 signaling pathway. , 2007, Current cancer drug targets.

[27]  A. Ranki,et al.  Notable losses at specific regions of chromosomes 10q and 13q in the Sézary syndrome detected by comparative genomic hybridization. , 1999, The Journal of investigative dermatology.

[28]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[29]  Benjamin J. Raphael,et al.  Mutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability, and cancer in mice , 2004 .

[30]  R. Eddy,et al.  The TCF8 gene encoding a zinc finger protein (Nil-2-a) resides on human chromosome 10p11.2. , 1992, Genomics.

[31]  A. Wynshaw-Boris,et al.  Inflammatory Disease and Lymphomagenesis Caused by Deletion of the Myc Antagonist Mnt in T Cells , 2006, Molecular and Cellular Biology.

[32]  Céline Rouveirol,et al.  Bioinformatics Original Paper Computation of Recurrent Minimal Genomic Alterations from Array-cgh Data , 2022 .

[33]  Céline Rouveirol,et al.  VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles , 2006, Bioinform..

[34]  S. Baylin,et al.  HIC1 hypermethylation is a late event in hematopoietic neoplasms. , 1997, Cancer research.

[35]  P. Nowell,et al.  Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. , 2006, The Journal of investigative dermatology.

[36]  S. Whittaker,et al.  Fine mapping of chromosome 10q deletions in mycosis fungoides and sezary syndrome: Identification of two discrete regions of deletion at 10q23.33–24.1 and 10q24.33–25.1 , 2005, Genes, chromosomes & cancer.

[37]  L. Penn,et al.  The myc oncogene: MarvelouslY Complex. , 2002, Advances in cancer research.

[38]  A. Wynshaw-Boris,et al.  Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis , 2003, The EMBO journal.

[39]  M. Henriksson,et al.  Proteins of the Myc network: essential regulators of cell growth and differentiation. , 1996, Advances in cancer research.

[40]  U. Landegren,et al.  Direct observation of individual endogenous protein complexes in situ by proximity ligation , 2006, Nature Methods.

[41]  L. Staudt,et al.  Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. , 2003, The Journal of biological chemistry.

[42]  Remco Dijkman,et al.  Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. , 2005, Blood.

[43]  B. Czepulkowski,et al.  Molecular cytogenetic analysis of cutaneous T‐cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides , 2002, The British journal of dermatology.

[44]  J. Scarisbrick,et al.  Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p. , 2001, The Journal of investigative dermatology.

[45]  H. Tanke,et al.  COBRA: combined binary ratio labeling of nucleic-acid probes for multi-color fluorescence in situ hybridization karyotyping , 2006, Nature Protocols.

[46]  A. Puisieux,et al.  Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. , 2004, Cancer cell.

[47]  L. Penn,et al.  Cancer therapeutics: targeting the dark side of Myc. , 2005, European journal of cancer.

[48]  Louise C. Showe,et al.  Classification and Prediction of Survival in Patients with the Leukemic Phase of Cutaneous T Cell Lymphoma , 2003, The Journal of experimental medicine.

[49]  S. Lowe,et al.  Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants , 2005, Nature.

[50]  C. Croce,et al.  Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Poustka,et al.  Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. , 2005, Cancer research.